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Drug delivery systems that increase the rate and/or quantity of drug release to the cytoplasm are
needed to enhance cytosolic delivery and to circumvent nonproductive cell trafficking routes. We have
previously demonstrated that poly(2-ethylacrylic acid) (PEAAc) has pH-dependent hemolytic properties,
and more recently, we have found that poly(2-propylacrylic acid) (PPAAc) displays even greater pH-
responsive hemolytic activity than PEAAc at the acidic pHs of the early endosome. Thus, these polymers
could potentially serve as endosomal releasing agents in immunotoxin therapies. In this paper, we
have investigated whether the pH-dependent membrane disruptive activity of PPAAc is retained after
binding to a protein. We did this by measuring the hemolytic activity of PPAAc-streptavidin model
complexes with different protein to polymer stoichiometries. Biotin was conjugated to amine-terminated
PPAAc, which was subsequently bound to streptavidin by biotin complexation. The ability of these
samples to disrupt red blood cell membranes was investigated for a range of polymer concentrations,
a range of pH values, and two polymer-to-streptavidin ratios of 3:1 and 1:1. The results demonstrate
that (a) the PPAAc-streptavidin complex retains the ability to lyse the RBC lipid bilayers at low
pHs, such as those existing in endosomes, and (b) the hemolytic ability of the PPAAc-streptavidin
complex is similar to that of the free PPAAc.
INTRODUCTION
There are now many biomolecular drugs in develop-
ment for the treatment of a wide variety of medical
ailments. These therapeutics include DNA for gene
therapies, oligonucleotides for antisense therapies, and
protein or peptide drugs and toxins for disease (e.g.,
cancer) therapies. A significant problem with the devel-
opment of many DNA and protein therapies is the
delivery of the biomolecule to the proper intracellular site.
The efficacy of DNA and protein therapeutics is often
limited by cellular trafficking processes that shunt the
agents to undesirable compartments or recycle them out
of the cell (1). Both DNA and protein therapeutics rely
on complicated trafficking routes initiated with receptor-
mediated endocytosis followed by transport through
endosomal, endoplasmic reticulum, and/or trans-Golgi
compartments. The efficiency of delivery across these
compartments to the cytosol, a necessary step in gene
therapy and many protein therapies, is often the limiting
factor in treatment efficacy.
When drugs and their complexes or conjugates with
carriers are endocytosed, they are often rapidly trafficked
from early endosomes to late endosomes, and eventually
to lysosomes where they are degraded (2). Internalized
drugs are not normally released into the cytoplasm of the
cell. An important example is the Immunotoxin family,
which exploits the specificity of monoclonal antibodies
for delivery of toxins to specific cellular and tissue
targets. The most commonly utilized toxins are ricin, a
plant toxin from the seeds of Ricinus communis, and the
bacterial toxins Diphtheria toxin and Pseudomonas exo-
toxin A (3). The efficacy of immunotoxins has been shown
to be dependent on the specific monoclonal antibody used
(3). Antibodies internalized by endocytosis are often
trafficked to lysosomes where they are degraded (4),
unlike the native toxin which is translocated into the
cytosol (5). Previous attempts to circumnavigate this
trafficking limitation include the modification of ricin A
chain by the addition of endoplasmic reticulum and Golgi
retention sequences (6), the use of endosome-destabilizing
peptides (7), and pH-triggered bispecific antibodies (8,
9).
We have been investigating pH-sensitive or “intel-
ligent” polymers that are capable of lysing red blood cells
at pH values observed in endosomes, while being non-
disruptive at a physiologic pH of 7.4. These are based on
R-alkyl acrylic acids. One example is poly(2-ethylacrylic
acid) (PEAAc),1 which has been shown to have pH-
dependent membrane-disruptive properties in liposomes
(10). A pH-triggered conformational change occurs at pH
† C.A.L. was awarded the 1998 Controlled Release Society-
Cygnus Graduate Student Award for Outstanding Work in Drug
Delivery for this work.
* To whom correspondence should be addressed.
‡ Department of Bioengineering.
§ Department of Medicine.
| Department of Chemical Eng’g.
⊥ Department of Bioengineering, Box 352255. Phone: 206-
543-9423.Fax: 206-543-6124.E-mail: hoffman@bioeng.washington.
edu.
# Department of Bioengineering, Box 352125. Phone: 206-
685-8148.Fax: 206-685-8256.E-mail: stayton@bioeng.washington.edu.
1 PEAAc, poly(2-ethylacrylic acid); PPAAc, poly(2-propylacryl-
ic acid); PPAAc-NH2, amine-terminated PPAAc; PPAAc-biotin,
biotinylated PPAAc; RBC, red blood cell; GPC, gel permeation
chromatography; NHS-LC-biotin, Sulfosuccinimidyl-6-(biotina-
mido)-6-hexanoate; HABA, hydroxyazobenzene-2-carboxylic acid;
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis.
401Bioconjugate Chem. 1999, 10, 401−405
10.1021/bc980109k CCC: $18.00 © 1999 American Chemical Society
Published on Web 04/24/1999
6.3 and below (11, 12). At these lower pH conditions,
PEAAc appears to permeabilize phosphatidylcholine (PC)
membranes, disrupt the lamellar structure of lipid bi-
layers, and form mixed micelles composed of polymer and
lipid. This process has a high efficiency, and the disrup-
tion of PC membranes in liposomes is general, as PEAAc
disrupts distearoyl, dipalmitoyl, dimyristoyl, dilauroyl,
and dioleoyl PC at low pH (10). These observations
suggested that these polymers may be useful as a new
class of drug delivery formulation components that
enhance delivery of biomolecules to the cytoplasm.
We have recently shown that PEAAc and PPAAc
efficiently induce red blood cell (RBC) hemolysis at lower
pHs, such as those existing in endosomes (13, 14). To be
effective in assisting endosomal release of therapeutics,
PEAAc and PPAAc must retain their hemolytic activity
when conjugated to a protein. In this paper, we have
prepared complexes of PPAAc and streptavidin at sto-
ichiometries of 1:1 and 3:1 polymer to protein. This serves
as a model to test the ability of the membrane-disruptive
polymer when linked to a protein to disrupt the lipid
bilayers of RBC membranes at the pHs existing in
endosomes.
EXPERIMENTAL PROCEDURES
Polymer Preparation. Amine-terminated PPAAc
(PPAAc-NH2) was synthesized using established chain-
transfer free-radical polymerization techniques. The pro-
pyl acrylic acid monomer was mixed with 1 mol %
initiator (azobisisobutyronitrile) and 4 mol % chain-
transfer agent (cysteamine). The mixture was degassed
by first freezing in liquid nitrogen, and subsequently
placed under vacuum and thawed. This was repeated
three times. Polymerization was carried out at 60 °C. Two
different PPAAc preparations were used in subsequent
experiments. The product of the first PPAAc polymeri-
zation reaction was fractionated by preparative gel
permeation chromatography (GPC), while ether precipi-
tation was used to remove small polymer chains from the
second PPAAc polymerization products.
Biotinylation of PPAAc. PPAAc-NH2 was biotinyl-
ated using sulfosuccinimidyl-6-(biotinamido)-6-hexanoate
(EZ-Link sulfo-NHS-LC-biotin, Pierce). PPAAc-NH2
was dissolved in 0.1 M sodium phosphate and 0.15 M
NaCl, pH 7.4. The NHS-LC-biotin was dissolved in water
at a concentration of 20 mg/mL and added to each of the
polymers at a 20 times molar excess. This was reacted
for 2 h at room temperature. The biotinylation was
repeated using a 15 times molar excess of biotin to
maximize the yield of biotinylated polymer molecules.
The samples were purified using a PD-10 desalting
column (Pharmacia) in order to ensure that all the free
biotin was removed. Absorbance at 220 nm was used to
detect which fractions contained polymer, and these
fractions were subsequently pooled.
Determination of Concentration of PPAAc-Bi-
otin. To determine the concentration of the biotinylated
PPAAc (PPAAc-biotin), the neutravidin-HABA dye assay
was used. A total of 1.5 mg of neutravidin (Molecular
Probes) was dissolved in 3 mL of 0.1 M sodium phosphate
and 0.15 M NaCl, pH 7.4. 4′-Hydroxyazobenzene-2-
carboxylic acid (HABA) (Sigma) was dissolved in 10 mM
NaOH at a concentration of 2.42 mg/mL (10 mM), and
75 íL was added to the protein. D-Biotin (Sigma) was
dissolved in 0.1 M sodium phosphate and 0.15 M NaCl,
pH 7.4, at a concentration of 0.5 mM. This solution was
added in 10 íL aliquots to the protein-HABA complex,
while the absorbance at 500 nm was measured after each
addition. By plotting the absorbance at 500 nm versus
the amount of biotin added, the calibration curve was
constructed. In parallel, incremental amounts of PPAAc-
biotin were added to the neutravidin and HABA solution,
and the absorbance at 500 nm was measured. The slope
of the curve generated was compared to the calibration
curve in order to determine the concentration.
Hemolysis Assay. The pH-dependent membrane-
disruptive activity of the PPAAc was measured using a
red blood cell (RBC) hemolysis assay. RBCs were har-
vested by centrifuging whole blood for 4 min. They were
washed three times with 100 mM dibasic sodium phos-
phate at the desired pH, and resuspended in the same
buffer to yield the initial volume. They were diluted 10
times in the same buffer, and 200 íL of this suspension
was used for each tube. This yields 108 RBCs per tube.
Each tube contained 800 íL of buffer, 200 íL of the RBC
suspension, and the polymer. Each sample was done in
triplicate, and was then repeated to verify reproducibility.
The tubes were incubated for an hour and a half in a 37
°C incubator. They were spun for 5 min at full speed in
the microcentifuge. Lysis was determined by measuring
the absorbance of the supernatant at 541 nm, reflecting
the amount of hemoglobin which had been released into
the supernatant. Percent hemolysis was calculated as-
suming 100% lysis to be measured by the hemoglobin
released by the red blood cells in water; controls of RBCs
in buffer with no polymer or in buffer with added
streptavidin were also run.
RESULTS
Polymer Preparation and Properties. To investi-
gate the importance of polymer polydispersity, the PPAAc
was fractionated by preparative GPC. The resulting
polymer mixture displayed an average molecular mass
that is equivalent to a PEG standard of 20 kDa. We found
that the hemolytic activity of the polymer was not
strongly dependent on the degree of polydispersity, as
ether-precipitated PPAAc with higher polydispersities
demonstrated the same hemolytic activity as fractionated
PPAAc.
Biotinylation of PPAAc. The neutravidin-HABA
assay was used to determine the fraction of PPAAc that
was biotinylated. The results demonstrate that no detect-
able quantity of the polymer remains unbiotinylated. In
addition, if unbiotinylated PPAAc remained in the mix-
ture, we would expect that the concentration dependence
of the hemolysis assay (below) would be shifted to reflect
the higher concentration added by the nonderivatized
polymer. The biotinylation of PPAAc was also verified
with an SDS-PAGE gel shift assay (Figure 2). Samples
of streptavidin alone, a physical mixture of streptavidin
and PPAAc-NH2, and a complex of streptavidin and
PPAAc-biotin were analyzed. The biotin-streptavidin
affinity was exploited to create the streptavidin-bioti-
nylated polymer complex as diagrammed in Figure 3.
Because the polymer is negatively charged at neutral pH,
the streptavidin-biotinylated PPAAc complex migrates
further in the gel. The physical mixture of streptavidin
and PPAAc-NH2 does not display a shift in electro-
phoretic mobility, indicating that the interaction between
streptavidin and PPAAc is specifically mediated by biotin.
Hemolysis Assay. The abilities of five different samples
to hydrolyze RBCs were compared. Test samples included
amine-terminated PPAAc; biotinylated PPAAc; a physical
mixture of streptavidin + amine-terminated PPAAc; a
streptavidin-biotinylated PPAAc complex; streptavidin
alone; and RBCs alone. The abilities of these samples to
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disrupt RBC membranes was investigated for a range of
polymer concentrations, a range of pH values, and for
two polymer-to-streptavidin ratios of 3:1 and 1:1. Figure
4 shows the effect of concentration of PPAAc on hemolysis
at pH 5 for a polymer-to-protein ratio of 3:1 (Figure 4A)
and 1:1 (Figure 4B). All the samples containing PPAAc
display equivalent hemolytic activity, as illustrated by
the superimposable curves of all derivatives of PPAAc,
which are normalized to the weight of PPAAc in each
sample. The maximum hemolytic capability is reached
at roughly 15 íg of PPAAc per 108 RBCs. Figure 5
displays the % hemolysis versus pH for PPAAc at a
concentration of 15 íg of polymer per 108 RBCs. Results
for polymer-to-protein ratios of 3:1 and 1:1 are presented
in Figure 5. A sharp dependence on pH is demonstrated,
with no significant hemolytic activity at pH 7.4 and a
maximum achieved by pH 6.3.
DISCUSSION
The results show that PPAAc hemolyzes red blood cells
with the same efficiency whether as a free polymer or
complexed via biotin to the protein streptavidin. The
hemolysis versus concentration profile is virtually identi-
cal for all samples containing PPAAc, indicating that the
hemolytic activity of PPAAc is not affected by its linkage
to a protein. Hemolysis by PPAAc reaches its maximum
Figure 1. Determination of PPAAc-biotin concentration using
the neutravidin/HABA assay.
Figure 2. (1) PPAAc-NH2 + Streptavidin, (2) PPAAc-biotin/
Streptavidin, (3) Streptavidin, (4) MW marker.
Figure 3. Schematic of the streptavidin-polymer model
system with the 3:1 and 1:1 polymer:protein ratios.
Figure 4. Concentration dependence of hemolytic activity for
PPAAc-NH2 (open squares), PPAAc-biotin (open circles), strepta-
vidin + PPAAc-NH2 physical mixture (closed squares), strepta-
vidin/PPAAc-biotin complex (closed circles), and streptavidin
alone (diamonds), with a polymer:protein stoichiometry of 3:1
(A) and 1:1 (B).
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at ca. 15 íg of polymer/108 red blood cells, which corre-
sponds to ca. 4.5  106 molecules of PPAAc/red blood cell.
Since polymer-to-protein ratios of 3:1 and 1:1 displayed
equivalent activity, we can conclude that it is unneces-
sary to have more than one polymer chain complexed per
protein molecule to achieve a highly efficient membrane
lytic activity. The hemolysis versus pH curves were also
identical for the free PPAAc and for the PPAAc-protein
conjugates at both PPAAc:protein ratios. The hemolysis
is strongly pH dependent, with the transition from
negligible lysis to maximum lysis occurring as the pH
decreases over a narrow range from pH 6.9 to 6.3. Thus,
linkage of PPAAc to the protein does not affect the pH-
dependent conformational and physical change of the
polymer and its ability to disrupt the RBC membrane.
We have not investigated the mechanism of this action,
but Tirrell and co-workers have studied the disruption
of liposomes by PEAAc (15). Their surface tensiometry
results were consistent with a micellization process
driven by hydrophobic interactions of the polymer and
the lipid bilayer. Such a mechanism is similar to that
seen for amphiphilic, R-helix-based polypeptides, but the
polymer is unlikely to adopt a secondary structure,
implying that the hydrophobic-to-hydrophilic ratio is the
most important factor in liposome micellization (15). They
also found that the rate of micellization was determined
by the rate and extent of PEAAc absorption, which in
turn was determined by the lateral compressibility of the
membrane (16). In comparison, melittin, the most mem-
brane disruptive peptide known, was less effective on a
molar basis (17).
The ability of the PPAAc-streptavidin complexes to
disrupt RBC membranes at lowered pHs, such as those
present in endosomes, suggests that these unusual pH-
responsive polymers represent a new avenue to facilitate
endosomal release and to improve the intracellular
delivery of protein or DNA therapeutics.
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